Base de dados : MEDLINE
Pesquisa : E02.183.750 [Categoria DeCS]
Referências encontradas : 463 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 47 ir para página                         

  1 / 463 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29019889
[Au] Autor:Luo W; Li YL; Chen YJ; Xiang Q; Chen H
[Ad] Endereço:aDepartment of Respiratory Medicine, The People's Hospital of Leshan, Leshan bDepartment of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan cThe First Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
[Ti] Título:High dose of nimustine as an add-on treatment for small cell lung cancer with intracranial metastasis: A case report and literature review.
[So] Source:Medicine (Baltimore);96(41):e8218, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Small cell lung cancer (SCLC) characterized by high degree of malignancy and rapid tumor progression. Intracranial metastases often appear at the time of the initial diagnosis or treatment. Besides of radiotherapy, chemotherapy is supposed to have limited effect. PATIENT CONCERNS: A 66-year-old male had blurred vision and unsteady step with moderate headache, nausea, vomit. DIAGNOSES: The patient was diagnosed with SCLC with intracranial metastases. INTERVENTIONS: High dose of nimustine (ACNU) (300 mg/m) add to the regimen containing carboplatin and irinotecan. OUTCOMES: Although the patient suffered severe myelosuppression, the intracranial lesion almost disappeared and maintained half a year. LESSONS: ACNU at a dose of 200 mg/m might be tolerable in combination with other chemotherapeutic drugs for the treatment of SCLC with intracranial metastases besides radiotherapy.
[Mh] Termos MeSH primário: Neoplasias Encefálicas
Neoplasias Pulmonares/patologia
Nimustina
Carcinoma de Pequenas Células do Pulmão/patologia
[Mh] Termos MeSH secundário: Idoso
Antineoplásicos/administração & dosagem
Antineoplásicos/efeitos adversos
Protocolos Antineoplásicos
Encéfalo/diagnóstico por imagem
Neoplasias Encefálicas/patologia
Neoplasias Encefálicas/secundário
Neoplasias Encefálicas/terapia
Quimiorradioterapia/métodos
Relação Dose-Resposta a Droga
Seres Humanos
Masculino
Estadiamento de Neoplasias
Exame Neurológico/métodos
Nimustina/administração & dosagem
Nimustina/efeitos adversos
Resultado do Tratamento
Transtornos da Visão/diagnóstico
Transtornos da Visão/etiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0S726V972K (Nimustine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171122
[Lr] Data última revisão:
171122
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171012
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008218


  2 / 463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28984783
[Au] Autor:Zhang Y; Chen Z; Li J
[Ad] Endereço:aDepartment of VIP Clinic, Tongji University South Branch of Shanghai East Hospital bDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College cDepartment of Oncology, Tongji University Shanghai East Hospital, Shanghai, China.
[Ti] Título:The current status of treatment for colorectal cancer in China: A systematic review.
[So] Source:Medicine (Baltimore);96(40):e8242, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers all over the world, but its epidemiology is obviously different in various regions. METHODS: The treatment of CRC also has varying characteristics due to differences in economy, geography, disease onset, chemotherapy, and other factors, although international guidelines are used to guide the treatment of CRC in China. RESULTS: This paper summarizes the current status of CRC treatment, including surgical therapy, neoadjuvant radiotherapy and chemotherapy, postoperative chemotherapy, targeted therapy, maintenance therapy, and immunotherapy, according to the clinical situation in China, so as to provide better therapy and improve clinical practice for patients with CRC. CONCLUSION: This research shows that the treatment of colorectal cancer continues to progress, and the patient's efficacy and quality of life have improved.
[Mh] Termos MeSH primário: Protocolos Antineoplásicos
Neoplasias Colorretais/terapia
[Mh] Termos MeSH secundário: China
Seres Humanos
Qualidade de Vida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008242


  3 / 463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28850960
[Au] Autor:Mehlis K; Becker C; Christ C; Laryionava K; Hiddemann W; Heußner P; Winkler EC
[Ad] Endereço:Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Medizinische Onkologie, Universitätsklinikum Heidelberg, Schwerpunkt "Ethik und Patientenorientierung in der Onkologie".
[Ti] Título:[Frequency and Timing of Decisions to Limit Intensive Medical Care and Tumor-Specific Therapy in University Hematology and Oncology].
[Ti] Título:Häufigkeit und Zeitpunkt von Entscheidungen gegen intensivmedizinische Maßnahmen und tumorspezifische Therapien in einer universitären Hämatologie und Onkologie..
[So] Source:Dtsch Med Wochenschr;142(17):e116-e123, 2017 Sep.
[Is] ISSN:1439-4413
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:Decisions to limit treatment (DLT) are important in order to prevent overtreatment at the end of life. However, they are not always discussed with the patient in advance or sufficiently documented. In a study to improve DLT in patients with an advanced hematological/ oncological disease we examined how often DLT precede deaths and how early they are determined. In a period of 6 months, 567 patients with advanced hematological/ oncological neoplasias had been recruited for the cross-sectional study at the University hospital in Munich. Using a standardized registration form an embedded researcher documented which DLT were determined for the patients and which of them were implemented until death. For 26 % (n = 147) of the 567 patients a DLT was determined. These DLT were mostly documented in writing from the beginning on (90 %; n = 132), 20 % (n = 30) were modified. The proportion of deceased patients with DLT was 82 % (n = 62 of 76 deceased). The median time between the initial determination of a DLT and the patient's death was 6 days at normal ward and 10.5 days at palliative ward. Compared to hematological patients, DLT were more frequently diagnosed in patients with an oncological disease (64 vs. 36 %) and the decisions were made slightly earlier (7 vs. 5 days before death). Our results show that DLT precede the death of many patients with a hematological/ oncological disease, but usually are made in the last week of life. This leads to the risk that the remaining few days to death are not sufficient for discussions with all parties involved and the planning of the end of life. These findings resulted in the development of an ethics policy for treatment limitation in cancer patients, which should support the concept of advance care planning. The project is funded by the German Cancer Aid.
[Mh] Termos MeSH primário: Neoplasias/epidemiologia
Neoplasias/terapia
Suspensão de Tratamento/estatística & dados numéricos
[Mh] Termos MeSH secundário: Planejamento Antecipado de Cuidados
Protocolos Antineoplásicos
Estudos Transversais
Alemanha/epidemiologia
Cuidados Paliativos na Terminalidade da Vida
Seres Humanos
Cuidados Paliativos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170830
[St] Status:MEDLINE
[do] DOI:10.1055/s-0043-103340


  4 / 463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28796723
[Au] Autor:Chang GJ
[Ad] Endereço:Houston, Texas.
[Ti] Título:Can Prognostic Scoring Tools Predict Treatment Outcomes?
[So] Source:Dis Colon Rectum;60(9):875-876, 2017 Sep.
[Is] ISSN:1530-0358
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Protocolos Antineoplásicos
Neoplasias Colorretais
[Mh] Termos MeSH secundário: Neoplasias Colorretais/mortalidade
Neoplasias Colorretais/patologia
Neoplasias Colorretais/terapia
Gerenciamento Clínico
Seres Humanos
Estadiamento de Neoplasias
Prognóstico
Projetos de Pesquisa
Resultado do Tratamento
[Pt] Tipo de publicação:EDITORIAL
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170811
[St] Status:MEDLINE
[do] DOI:10.1097/DCR.0000000000000820


  5 / 463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28704720
[Au] Autor:Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Alghamdi K; Elbjeirami WM
[Ad] Endereço:Hematology Department, King Abdullah Medical City- HC, Saudi Arabia. Electronic address: draalabdulwahab@gmail.com.
[Ti] Título:The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
[So] Source:Leuk Res;60:58-62, 2017 Sep.
[Is] ISSN:1873-5835
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The use of intensive pediatric protocols for the treatment of ALL is being extended to older adults. AIM OF THE STUDY: Analysis of the efficacy and toxicity results of pediatric DFCP vs. classic Hyper-CVAD protocol for the treatment of patients with ALL < 50 Y. PATIENTS AND METHODS: A retrospective single center comparative analysis of DFCP & classic Hyper-CVAD for first line treatment of patients with ALL < 50 Y. RESULTS: 73 patients were included, 43 received DFCP and 30 received Hyper-CVAD protocol. CR rate was 90.7% for DFCP vs. 83.7 for Hyper-CVAD (p 0.7). 3 Y Leukemia free survival was 57.4% (70.9% for DFCP vs. 41.6% Hyper-CVAD P 0.1) while 3Y OS was 62.6%% for the whole group, 72.6% DFCP vs. 48.5% Hyper-CVAD, P 0.04. Those with age <21 Y, had significantly longer 3 Y LFS and OS (P 0.04, 0.02, respectively). TOXICITY: pancreatitis occurred in 5 patients with DFCP and it was related to Asparginase and in 1 patient on Hyper-CVAD related to gall stones. Osteonecrosis affected 5 patients on DFCP. IN CONCLUSION: pediatric protocols are feasible in patients younger than 50 Y and they are more active than classic adult protocols. Although modifications of adult protocols may improve their results, this had to be investigated in randomized controlled trials.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Protocolos Antineoplásicos/normas
Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Criança
Ciclofosfamida/efeitos adversos
Ciclofosfamida/uso terapêutico
Dexametasona/efeitos adversos
Dexametasona/uso terapêutico
Intervalo Livre de Doença
Doxorrubicina/efeitos adversos
Doxorrubicina/uso terapêutico
Feminino
Seres Humanos
Masculino
Meia-Idade
Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações
Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade
Estudos Retrospectivos
Taxa de Sobrevida
Vincristina/efeitos adversos
Vincristina/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
5J49Q6B70F (Vincristine); 7S5I7G3JQL (Dexamethasone); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170714
[St] Status:MEDLINE


  6 / 463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28534324
[Au] Autor:Liang P; Hu X
[Ti] Título:[Strategies of diagnosis and treatment for peritoneal metastasis of gastric cancer].
[So] Source:Zhonghua Wei Chang Wai Ke Za Zhi;20(5):500-503, 2017 May 25.
[Is] ISSN:1671-0274
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:Peritoneal metastasis of gastric cancer is the main cause of death in gastric cancer patients. Peritoneal metastasis of gastric cancer is difficult to diagnose in its early stage due to lack of obvious clinical signs and symptoms, and poor treatment outcomes and prognosis are often associated with late stage peritoneal metastasis. Therefore, it is crucial to utilize effective early diagnostic tools and to improve the long-term outcomes and the prognosis of patients with advanced gastric cancer. Recently, systemic chemotherapy and intraperitoneal chemotherapy are the first line therapy, and cytoreductive operation plus abdominal cavity thermochemotherapy may be the best method in the treatment of peritoneal metastasis. However, conversion therapy has been gradually incorporated into the treatment of peritoneal metastasis of gastric cancer because of the better efficacy and the higher survival.
[Mh] Termos MeSH primário: Protocolos Antineoplásicos
Neoplasias Peritoneais/diagnóstico
Neoplasias Peritoneais/secundário
Neoplasias Gástricas/patologia
[Mh] Termos MeSH secundário: Antineoplásicos/uso terapêutico
Terapia Combinada/métodos
Procedimentos Cirúrgicos de Citorredução
Detecção Precoce de Câncer/métodos
Seres Humanos
Hipertermia Induzida
Prognóstico
Neoplasias Gástricas/mortalidade
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170524
[St] Status:MEDLINE


  7 / 463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28404860
[Au] Autor:Venere M
[Ad] Endereço:Department of Radiation Oncology and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43017, USA. Email: monica.venere@osumc.edu.
[Ti] Título:Vitamin C puts the pedal to the metal.
[So] Source:Sci Transl Med;9(385), 2017 Apr 12.
[Is] ISSN:1946-6242
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Increased iron in cancer cells drives selective sensitization of tumors to ascorbate treatment to prolong survival.
[Mh] Termos MeSH primário: Ácido Ascórbico/uso terapêutico
[Mh] Termos MeSH secundário: Protocolos Antineoplásicos
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
PQ6CK8PD0R (Ascorbic Acid)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170626
[Lr] Data última revisão:
170626
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE


  8 / 463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28403089
[Au] Autor:Cui R; Yuan F; Wang Y; Li X; Zhang Z; Bai H
[Ad] Endereço:aDepartment of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University bDepartment of Obstetrics and Gynecology, the affiliated hospital Qingdao University cDepartment of Pathology, Beijing Chao-Yang Hospital, Capital Medical University dDepartment of Pathology, the affiliated hospital Qingdao University, Beijing, China.
[Ti] Título:Clinicopathological characteristics and treatment strategies for patients with low-grade endometrial stromal sarcoma.
[So] Source:Medicine (Baltimore);96(15):e6584, 2017 Apr.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To investigate and evaluate the clinicopathological characteristics and treatment strategies for patients with low-grade endometrial stromal sarcoma (LG-ESS).The medical records of LG-ESS patients who were treated at 2 cancer referral centers from January 2005 to December 2015 were retrospectively reviewed.Twenty patients with LG-ESS met the inclusion criteria and were included in this analysis. Hysterectomy with bilateral salpingo-oophorectomy was the mainstay of surgery. Lymphadenectomy was performed in 12 (60%) cases, and no positive nodes were identified. CD10 was the most commonly used immunohistochemistry marker, followed by smooth muscle actin (SMA), estrogen receptor (ER), desmin, progesterone receptor (PR), and S-100; the positivity rates of these markers were 88.2%, 66.7%, 75.0%, 16.7%, 88.9%, and 0, respectively. Postoperative chemotherapy, radiotherapy, and hormonal treatment were provided alone or in combination in 10 (50%) patients, 4 (20%) patients, and 1 (5%) patient, respectively. One patient developed lung metastasis at initial diagnosis, and 2 (10%) patients had recurrence with distant metastasis. They all underwent complete or incomplete resection followed by hormonal treatment. The overall survival time of these patients was 66, 89, and 109 months at last contact, respectively. The 5-year and 10-year disease-free survival rates for the entire cohort were 90% and 72%, respectively. No patients died of the disease.CD10/SMA/ER/PR in combination with desmin/S-100 might improve the diagnostic accuracy. Surgical resection is the foremost treatment for LG-ESS patients with recurrence or distant metastasis. Hormonal treatment may be beneficial for unresectable or residual tumors.
[Mh] Termos MeSH primário: Neoplasias do Endométrio/patologia
Neoplasias do Endométrio/terapia
Tumores do Estroma Endometrial/patologia
Tumores do Estroma Endometrial/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Antineoplásicos Hormonais/uso terapêutico
Protocolos Antineoplásicos
Biomarcadores Tumorais/análise
Terapia Combinada
Intervalo Livre de Doença
Feminino
Seres Humanos
Histerectomia
Imuno-Histoquímica
Meia-Idade
Neprilisina/análise
Ovariectomia/métodos
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0 (Biomarkers, Tumor); EC 3.4.24.11 (Neprilysin)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170430
[Lr] Data última revisão:
170430
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006584


  9 / 463 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28399522
[Au] Autor:Thoennissen GB; Görlich D; Bacher U; Aufenberg T; Hüsken AC; Hansmeier AA; Evers G; Mikesch JH; Fritz F; Bokemeyer C; Müller-Tidow C; Stelljes M; Mesters RM; Krug U; Kropff MH; Thoennissen NH; Berdel WE
[Ad] Endereço:Department of Oncology, Hematology, and Bone Marrow Transplantation with Section of Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
[Ti] Título:Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.
[So] Source:Acta Haematol;137(3):163-172, 2017.
[Is] ISSN:1421-9662
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Within this retrospective single-center study, we analyzed the survival of 320 multiple myeloma (MM) patients receiving melphalan high-dose chemotherapy (HDCT) and either single (n = 286) or tandem (n = 34) autologous stem cell transplantation (ASCT) from 1996 to 2012. Additionally, the impact of novel induction regimens was assessed. Median follow-up was 67 months, median overall survival (OS) 62 months, median progression-free survival (PFS) 33 months (95% CI 27-39), and treatment-related death (TRD) 3%. Multivariate analysis revealed age ≥60 years (p = 0.03) and stage 3 according to the International Staging System (p = 0.006) as adverse risk factors regarding PFS. Median OS was significantly better in newly diagnosed MM patients receiving induction therapy with novel agents, e.g., bortezomib, thalidomide, or lenalidomide, compared with a traditional regimen (69 vs. 58 months; p = 0.01). More patients achieved at least a very good partial remission in the period from 2005 to 2012 than from 1996 to 2004 (65 vs. 30%; p < 0.001), with a longer median OS in the later period (71 vs. 52 months, p = 0.027). In conclusion, our analysis confirms HDCT-ASCT as an effective therapeutic strategy in an unselected large myeloma patient cohort with a low TRD rate and improved prognosis due to novel induction strategies.
[Mh] Termos MeSH primário: Mieloma Múltiplo/tratamento farmacológico
Mieloma Múltiplo/terapia
Transplante de Células-Tronco
[Mh] Termos MeSH secundário: Adulto
Idoso
Antineoplásicos Alquilantes/administração & dosagem
Protocolos Antineoplásicos
Estudos de Coortes
Terapia Combinada
Intervalo Livre de Doença
Feminino
Seres Humanos
Quimioterapia de Indução
Masculino
Melfalan/administração & dosagem
Meia-Idade
Prognóstico
Estudos Retrospectivos
Transplante Autólogo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); Q41OR9510P (Melphalan)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.1159/000463534


  10 / 463 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28302823
[Au] Autor:Lord CJ; Ashworth A
[Ad] Endereço:The Cancer Research UK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. chris.lord@icr.ac.uk alan.ashworth@ucsf.edu.
[Ti] Título:PARP inhibitors: Synthetic lethality in the clinic.
[So] Source:Science;355(6330):1152-1158, 2017 03 17.
[Is] ISSN:1095-9203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality, a genetic concept proposed nearly a century ago. Tumors arising in patients who carry germline mutations in either or are sensitive to PARPi because they have a specific type of DNA repair defect. PARPi also show promising activity in more common cancers that share this repair defect. However, as with other targeted therapies, resistance to PARPi arises in advanced disease. In addition, determining the optimal use of PARPi within drug combination approaches has been challenging. Nevertheless, the preclinical discovery of PARPi synthetic lethality and the route to clinical approval provide interesting lessons for the development of other therapies. Here, we discuss current knowledge of PARP inhibitors and potential ways to maximize their clinical effectiveness.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Neoplasias/tratamento farmacológico
Neoplasias/genética
Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico
Mutações Sintéticas Letais
[Mh] Termos MeSH secundário: Antineoplásicos/química
Antineoplásicos/farmacologia
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Protocolos Antineoplásicos
Proteína BRCA2/genética
Ensaios Clínicos como Assunto
Dano ao DNA/genética
Reparo do DNA/genética
Mutação em Linhagem Germinativa
Seres Humanos
Inibidores de Poli(ADP-Ribose) Polimerases/química
Inibidores de Poli(ADP-Ribose) Polimerases/farmacologia
Ubiquitina-Proteína Ligases/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (BRCA2 Protein); 0 (BRCA2 protein, human); 0 (Poly(ADP-ribose) Polymerase Inhibitors); EC 2.3.2.27 (BRAP protein, human); EC 2.3.2.27 (Ubiquitin-Protein Ligases)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170318
[St] Status:MEDLINE
[do] DOI:10.1126/science.aam7344



página 1 de 47 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde